Key result
By the end of a one-year follow-up, adherence to rivaroxaban was significantly higher at 59.4% compared to 8.7% for warfarin among elderly patients with nonvalvular atrial fibrillation.
Why the study?
The study assessed adherence to anticoagulant therapy with warfarin versus rivaroxaban in elderly patients with nonvalvular atrial fibrillation.
Does rivaroxaban improve adherence to treatment compared to warfarin in elderly patients with nonvalvular atrial fibrillation?
Observational (n=322)
Does rivaroxaban improve adherence to treatment compared to warfarin in elderly patients with nonvalvular atrial fibrillation?
Absolute Event Rate: 59.4% vs 8.7%
p-value: p=<0.05
In elderly patients with nonvalvular atrial fibrillation, adherence to rivaroxaban is substantially higher than to warfarin at one year, though cost and INR monitoring remain key barriers respectively.
May support rivaroxaban preference for adherence in elderly NVAF; hypothesis-generating and requires RCT confirmation.
Objectives assessment of adherence to treatment in elderly patients with nonvalvular atrial fibrillation who were prescribed anticoagulant therapy with vitamin K antagonist, warfarin, and a new oral anticoagulant rivaroxaban. Material and methods. During the study, 322 patients with atrial fibrillation of nonvalvular etiology were observed. Depending on the type of anticoagulant taken, the patients were divided into 2 groups: the first group included 253 (78.6%) people who took warfarin, the second group 69 (21.4%) people, who were prescribed a new oral anticoagulant rivaroxaban. Results. By the end of the one-year follow-up from the start of anticoagulant treatment, only 8.7% of patients in the first group followed the doctor's prescription; the second group had 59.4% of adherent patients. The vast majority of patients refused warfarin therapy due to the inability to control INR. In the case of the appointment of rivaroxaban, the reason for the refusal to take was the high cost of the drugs. Conclusion. Effective prevention of thromboembolic complications in atrial fibrillation requires the development of appropriate measures to improve adherence to treatment.
No takes yet. Share an insight, caveat, or question.
Kanat kyzy Bazira (2021) conducted an observational in Nonvalvular atrial fibrillation (n=322). Rivaroxaban vs. Warfarin was evaluated on Adherence to anticoagulant therapy at 1 year (p=<0.05). By the end of a one-year follow-up, adherence to rivaroxaban was significantly higher at 59.4% compared to 8.7% for warfarin among elderly patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: